Interview with Dr. Peter Traber, CEO of Galectin Therapeutics

Sully and Russ T Nailz interview Galectin Therapeutics CEO, Dr. Peter Traber. Dr. Traber discusses the very real progress that GALT is making with respect to liver diseases worldwide.

Galectin Therapeutics is a biotechnology company focused on discovery and development. GALT applies their leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer.